DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Quinaretic (Quinapril Hydrochloride / Hydrochlorothiazide) - Summary

 
 



BOXED WARNING

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, QUINARETIC should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.

 

QUINARETIC SUMMARY

QUINARETIC is a fixed-combination tablet that combines an angiotensin-converting enzyme (ACE) inhibitor, quinapril hydrochloride, and a thiazide diuretic, hydrochlorothiazide.

QUINARETIC is indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION).

In using QUINARETIC, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis).

Angioedema in Black Patients:

Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.


See all Quinaretic indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Quinaretic (Quinapril / Hydrochlorothiazide)

30-Minute BP Monitoring Reduces White-Coat Hypertension (CME/CE)
Source: MedPage Today Nephrology [2017.03.14]
(MedPage Today) -- But experts question feasibility, need in primary care setting

Study reveals link between hypertension and brain changes in rats
Source: Hypertension News From Medical News Today [2017.03.10]
New research investigates the changes in brain activity and arterial blood flow that occur with the onset of hypertension in rats.

Evidence review supports pediatric use of PDE-5 inhibitors for pulmonary hypertension
Source: Hypertension News From Medical News Today [2017.02.28]
A systematic review of the comparative effectiveness and safety of phosphodiesterase type 5 (PDE-5) inhibitors in pediatric patients with pulmonary hypertension published in Pediatrics demonstrates...

Late-onset hypertension may lower dementia risk, study finds
Source: Hypertension News From Medical News Today [2017.01.17]
For the first time, a study investigates the link between high blood pressure later in life and the risk of dementia and cognitive decline.

New guidelines raise upper hypertension limit for 'otherwise healthy' over-60s
Source: Hypertension News From Medical News Today [2017.01.17]
New guidelines say treat otherwise healthy patients aged 60 and older when persistent systolic blood pressure is at or above 150 mm Hg, not 140 mm Hg.

more news >>


Page last updated: 2017-03-14

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015